Unichem Laboratories reported a consolidated net loss of Rs 17.19 crore in Q4 March 2020 compared with net profit of Rs 37.99 crore in Q4 March 2019.
Net sales fell 14.6% year-on-year (YoY) to Rs 320.23 crore during the quarter. Profit before tax stood at Rs 0.44 crore in Q4 FY20, down 98.5% from Rs 28.98 crore in Q4 FY19. Current tax expense slumped 59.10% to Rs 2.92 crore during the period under review. Total R&D expenditure fell 11.3% to Rs 31.27 crore during the quarter compared with Rs 35.24 crore in the same period last year.
With respect to the impact of COVID-19 on its business operations, the company said, "The actual impact of the global health pandemic may be different from that which has been estimated, as the COVID-19 situation evolves in India and globally. The Company will continue to closely monitor any material changes to future economic conditions."
Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world.
Shares of the drug maker fell 4.62% to Rs 158.80 on Friday.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
